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Inhaled corticosteroids (ICS) are frequently recommended for the treatment of asthma and COPD, often
in combination with long-acting beta2-agonists (LABA), depending on the severity of the disease and/or
on the speciﬁc phenotype. Several ICS/LABA combinations are currently available that differ in their
pharmacokinetic characteristics and dose of both components. Thus, this review assesses differences in
the efﬁcacy and the safety proﬁles of the ICS components in the two more frequently used ICS/LABA
combinations (budesonide/formoterol and ﬂuticasone/salmeterol) for the management of COPD.
Whereas the basic mechanism of action is similar for all ICS (bindingwith the intracellular glucocorticoid
receptor, which mediates both genomic and non genomic effects), the pharmacokinetic and characteristics
of ICS are quite different in terms of receptor afﬁnity, bioavailability, lipophilicity and drug persistence in
the airways. Fluticasone persists longer in airway mucus and requires more time to dissolve in the lining
ﬂuid and then enter the airway wall, whereas budesonide is cleared more quickly from the airways.
Comparative efﬁcacy of the two major ICS/LABA combinations recommended for the treatment of COPD
show similar efﬁcacy in terms of reduction of exacerbations, improvement in forced expiratory volume in
the ﬁrst second (FEV1) and quality of life. One retrospective cohort study suggested a greater efﬁcacy for the
budesonide/formoterol combination on hospital or emergency department admissions, oral corticosteroid
courses, and addition of tiotropium, and an observational real-life study reported a greater reduction of
COPD exacerbations with budesonide/formoterol than with ﬂuticasom/salmeterol combination.
Among the potential side effects of chronic ICS treatment in patients with COPD, recently the use of
ﬂuticasone or ﬂuticasone/salmeterol combination has been associated with a higher prevalence of
pneumonia in the major long-term studies. On the other hand, no similar increased risk of pneumonia
has been reported in patients with COPD treated with the budesonide/formoterol combination. A recent
population-based cohort study from the Quebec database showed that the adjusted odds ratio for having
severe pneumonia was higher for ﬂuticasone (2.1) than for budesonide (1.17) or other ICS (1.41). Of the
ICS studied, only ﬂuticasone demonstrated a dose-related increase in risk of pneumonia in patients with
COPD. This difference between ﬂuticasone and budesonide may be explained by the longer retention of
ﬂuticasone in the airways, with potentially greater inhibition of type-1 innate immunity.
Therefore, the risk:beneﬁt ratio should be evaluated thoroughly when choosing an ICS/LABA combi-
nation for patients with COPD.
© 2014 Published by Elsevier Ltd.ar Department, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy. Tel.: þ39 050 995365; fax: þ39 050 580124.
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Determinants of efﬁcacy and therapeutic index in the different ICS (adapted with
permission from Raissay et al. [6].
Binding
afﬁnity
Oral
bioavailability
Systemic
clearance
Volume of
distributionAsthma and chronic obstructive pulmonary disease (COPD) are
major diseases, both in terms of their prevalence in the general
population and the associated socio-economic burden. Those are
characterized by variable degrees of airway obstruction, and the
two diseases involve underlying inﬂammation of the bronchial wall
and lung parenchyma that differ in terms of their characteristics
and response to treatment.
Inhaled corticosteroids (ICS) are the most effective anti-
inﬂammatory agents used to treat airway diseases, because of
their role in modifying several inﬂammatory cells and pathways
involved in asthma and COPD [1]. In asthma, ICS are the corner-
stone of pharmacologic treatment, and are recommended in all
symptomatic patients, at doses that differ depending on disease
severity, asmonotherapy or in combinationwith long-acting beta2-
agonists (LABA) or leukotriene receptor antagonists [2]. In COPD,
ICS represent a second step treatment, and those are in general
recommended in more severe patients (FEV1  50% of predicted),
who remain symptomatic despite long-acting bronchodilator
treatment, and/or patients with frequent exacerbations [3].
Recently, a special clinical and functional situation, characterized
by features typical of both asthma and COPD (asthma-COPD overlap
syndrome, ACOS) has been described and well characterized in
terms of diagnosis and treatment; ICS, together with long-acting
bronchodilators, are recommended for treating these patients [4].
Currently, several ICS/LABA combinations are available: the
older ﬂuticasone propionate/salmeterol (FS) and budesonide/for-
moterol (BF) combinations, and the more recent beclometasone/
formoterol (BDP/F), ﬂuticasone propionate/formoterol (FF), and
mometasone/formoterol (MF) combinations. While the ﬁrst two
combinations are indicated for treatment of both asthma and COPD,
the others are now recommended only for treating asthma.
Furthermore, also ﬂuticasone furoate/vilanterol (FV) combination
has been introduced on the market, with the indication for COPD
treatment in US only, but very limited data are available with this
combination.
Despite sharing a similar basic mechanism of action, ICS differ in
terms of pharmacokinetic characteristics, and this may determine
important difference in their efﬁcacy and safety. Therefore, an
important question is whether all ICS are equivalent in the man-
agement of airway diseases. Very few comparative studies have
been conducted, and only indirect comparisons are available.
This reviewwill attempt to understand if there are differences in
the efﬁcacy and in the safety proﬁles of the ICS included in the ICS/
LABA combinations currently used for the management of COPD. In
particular, the aim of this review was to compare the two more
frequently used ICS/LABA combinations in COPD patients (bude-
sonide/formoterol and ﬂuticasone/salmeterol) in terms of efﬁcacy
(reduction in the rate of exacerbations) and of safety, with special
attention to the risk of pneumonia.(RRA)a (%) (L/h) (L)
BDP MDI, 40 and 80 mcg 0.4 20 150 424
BUD DPI, 90 and 180 mcg 9.4 11 84 280
CIC MDI, 80 and 160 mcg 0.12 <1 152 897
FLU MDI, 80 mcg 1.8 20 58 96
FP MDI, 44, 110 and
220 mcg
18 1 66 602
FP DPI, 50, 100 and
250 mcg
18 1 66 602
MF DPI, 110 and 220 mcg 23 <1 53 332
BDP ¼ beclomethasonedipropionate; BUD ¼ budesonide; CIC ¼ ciclesonide;
FLU ¼ ﬂunisolide; FP ¼ ﬂuticasone propionate; MF ¼ mometasonefuroate;
MDI ¼ metered dose inhaler; DPI ¼ dry powder inhaler.
a Receptor binding affinities of ICSs relative to dexamethasone equal to 1; RRA:
relative receptor afﬁnity.2. Pharmacology of inhaled corticosteroids
Corticosteroid (CS) effects on target cells are mediated by
mechanisms that involve binding to DNA, or mechanisms that are
independent of DNA binding [5]. The genomic effect of corticoste-
roids occurs through binding of the CS molecule to cytoplasmic
glucocorticoid receptors (GR), after which the CS-GR complex en-
ters the nucleus and interacts with speciﬁc steroid-responsive DNA
sequences, leading to trans-activation of genes encoding tran-
scription factors that promote the release of anti-inﬂammatory
compounds (e.g., lipocortin) and to downregulate the release of
pro-inﬂammatory cytokines. This activity of the CS-GR complexthe local chromatin structure and de-represses transcription of
nuclear sequences, allowing them to be transcribed. Whereas, the
effect of CS independent of direct DNA binding is due to the ability
of the CS-GR complex to bind certain signal-dependent transcrip-
tion factors (e.g., nuclearfactorkB (NFkB), activator protein 1 (AP-1))
that are normally activated as a result of signal transduction cas-
cades originating from the binding of circulating cytokines to
speciﬁc cell receptors. Binding of these transcription factors by CS-
GR neutralises their ability to transactivate genes encoding pro-
inﬂammatory molecules (trans-repression). The intrinsic binding
activity of a CS for the GR is the main determinant of its efﬁcacy for
both of these mechanisms; however, other pharmacokinetic char-
acteristics (e.g., solubility, retention in the cell, rate of inactivation)
are also important.
In Table 1 are reassumed the pharmacokinetic and pharmaco-
dynamic characteristics of the available ICS, data extensively
reviewed elsewhere [6e9]. Binding afﬁnity for the GR is particu-
larly high for ﬂuticasone andmometasone, followed by budesonide
and by other ICS. Systemic bioavailability is negligible for ﬂutica-
sone, mometasone and ciclesonide, but it is also low for budeso-
nide, whereas it is high for beclometasone and ﬂunisolide. The
volume of distribution is large for ﬂuticasone and ciclesonide, due
to their high liposolubility, intermediate for budesonide, mometa-
sone, and beclometasone, and low for ﬂunisolide. The binding af-
ﬁnity, combined with the percent of lung delivery obtained with
the various formulations (metered-dose inhalers, MDI, vs dry
powder inhalers, DPI) available for the different compounds, allows
calculation of the equivalent doses of each ICS. These data are
available in several equivalence tables, for example, in the inter-
national GINA guidelines. For the most frequently used ICS
(included in ICS/LABA combinations) for the treatment of asthma
and COPD, 400 mcg of beclometasone in a hydroﬂuoroalkane
(HFA)-propelled pressurised metered-dose inhaler (pMDI) is
equivalent to 800mcg of DPI budesonide and to 500mcg pMDI/DPI
ﬂuticasone [2].
Currently only ﬂuticason/salmeterol and budesonid/formoterol
combinations are licenced for the treatment of COPD, therefore, we
will continue with a pharmacologic comparison of ﬂuticasone and
budesonide. As mentioned before, ﬂuticasone has higher intrinsic
afﬁnity and lower systemic bioavailability than budesonide. How-
ever, the most important difference between these two compounds
is the higher lipophilicity (log K) of ﬂuticasone (log K ¼ 4.5) versus
that for budesonide (log K ¼ 3.7). This may explain the larger vol-
ume of distribution of ﬂuticasone. Another important difference is
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under the curve (AUC) of plasma concentrations obtained in the
ﬁrst hours of a single inhalation of ICS. This index of rapid systemic
availability is lower in patients with airway obstruction (like pa-
tients with severe COPD) than in normal subjects, due to lower drug
penetration and deposition in patients with high airway resistance.
However, the AUC is consistently lower for ﬂuticasone (1.50 and
0.84 mM/h in normal subjects and COPD patients respectively) than
for budesonide (6.21 and 3.07 mM/h, respectively) [10]. This may be
explained by the consideration that inhaled ﬂuticasone persists
longer in the mucus and more time is required for dissolving in the
lining ﬂuid, and then for penetrating in the airway wall where it
may exert its anti-inﬂammatory effect. Other data which support
this explanation are the maximum concentration reached in the
blood (Cmax: 0.09 vs 1.08 mM, for ﬂuticasone and budesonide
respectively) and the time to maximum concentration (Tmax: 50.8
vs 15.5 min, respectively) after a single inhaled dose, so that the
mean residence time (MRT) in the airways is higher for ﬂuticasone
than for budesonide (MRT: 12.8 vs 4.41 h, respectively). This high
lipophilicity of ﬂuticasone may explain the high local activity and
the long duration of action, whereas for budesonide the long
duration of action (demonstrated in all clinical trials) may result
from a different mechanism: active intracellular esteriﬁcation and
deposition, with subsequent prolonged release of the drug through
lipolysis. Therefore, when sputumwas collected in the ﬁrst 6 h after
a single administration of equivalent doses of ﬂuticasone or
budesonide, the sputum ICS concentration was 5-fold higher with
ﬂuticasone, although the cumulative sputum volume was similar
[10]. This supports the contention that ﬂuticasone persists longer
than budesonide in the airways, andmight explain the high efﬁcacy
of this drug on airway inﬂammation.
On the other hand, the more balanced lipophilic/hydrophilic
characteristics of budesonide may explain its higher efﬁcacy in
terms of rapid onset of action, in part due to the strong non-
genomic effects of budesonide. Several in vitro and in vivo exper-
imental studies have conﬁrmed that an anti-inﬂammatory effect of
budesonide may be detected a few hours after administration
[11,12].
3. Comparative clinical efﬁcacy of ﬂuticasone/salmeterol and
budesonide/formoterol combinations in COPD
While several randomized clinical trials (RCTs) in asthma have
directly compared these two formulations, no such data have been
reported for COPD. In asthma, budesonide/formoterol was
demonstrated as effective as ﬂuticasone/salmeterol when admin-
istered regularly at equivalent daily doses [13], while it resulted
more effective than ﬁxed higher dose ﬂuticasone/salmeterol com-
bination in improving lung function, quality of life, and in reducing
the incidence of severe asthma exacerbations, hospitalization and
emergency department, when used according to the maintenance
and reliever strategy [14,15].
In COPD, both ﬂuticasone/salmeterol and budesonide/for-
moterol are thought to reduce exacerbations to a similar degree,
but no double-blind prospective RCTs have compared exacerbation
rates between these two combinations. Within the limits imposed
by the difﬁculty of comparing studies conducted in different COPD
populations, with different inclusion criteria, concomitant medi-
cations, duration of treatment and endpoints, it appears that the
efﬁcacy of these two combinations is similar. In the TRISTAN study
Calverley et al. compared the effects of a combination therapy with
salmeterol 50 mg and ﬂuticason propionate 500 mg in a single de-
vice, with the individual component and placebo, for 12months. All
active treatments improved lung function, symptoms, health status
and reduced frequency of exacerbations per patient year comparedwith placebo. Combination therapy was better than ﬂuticasone
propionate alone and salmeterol alone in terms of pre-treatment
and post-bronchodilator FEV1 (the primary outcome) [16]. Simi-
larly in the TORCH study, a randomized double-blind trial for a
period of three years, the comparison between the combination
treatment with salmeterol (50 mg) and ﬂuticasone (500 mg)
administered together in a single inhaler versus the individual
components and placebo showed a signiﬁcant reduction in the
mean moderate-severe exacerbation rate per participant per year
in favour of the all treatments when compared with placebo
(exacerbation rate/pt/yr: salmeterol/ﬂuticasone 0.85, salmeterol
0.97, ﬂuticasone propionate 0.93 vs placebo: 1.13, p < 0.001) and a
non signiﬁcant reduction in exacerbation requiring hospitalization
(exacerbation rate/pt/yr: salmeterol/ﬂuticasone 0.16 salmeterol
0.16, ﬂuticasone propionate 0.17 vs placebo: 0.19). For lung func-
tion, the mean baseline FEV1 in the combination-therapy group
increase of 0.029 L (L) a signiﬁcant improvement versus placebo,
salmeterol and ﬂuticasone propionate
(0.062(L), 0.021(L), 0.015(L) respectively; p < 0.001) [17].
We can observe similar results also in the two studies conducted
with the budesonide-formoterol combination. In a ﬁrst study Cal-
verley et al. observed a signiﬁcant reduction in total number of
annual exacerbation with budesonide/formoterol (320/9 mg twice
daily) vs PL (1.38 vs 1.80) and in patients treated with budesonide/
formoterol the persistence of the improvement in the FEV1 value
obtained during the run-in period in which patients received oral
prednisolone (30mg) o.d. and inhaled formoterol; in contrast, FEV1
declined greatly and rapidly with all other treatments (budesonide
400 mg end formoterol 9 mg) [18]. In the study of Szafranski et al.
were conﬁrmed similar results with a signiﬁcant reduction in se-
vere exacerbations in the group of patients treated with budeso-
nide/formoterol vs formoterol 9 mg and placebo (exacerbation rate:
budesonide/formoterol 1.42; budesonide 1.59; formoterol: 1.89;
placebo: 1.87). The FEV1 signiﬁcantly improved in all groups of
treatment [19]. A Cochrane Systematic review including ﬁve studies
with FS and four with BF revealed a similar OR in favour of the two
combinations vs LABA alone (0.77 vs 0.73, respectively) in terms of
reduction of exacerbation rates [20].
One propensity matched COPD cohort study of 1-year duration
conducted in Canada suggested that differences in efﬁcacy might
exist between the ICS/LABA combinations in favour of budeso-
nide/formoterol. From a large Canadian database, patients with a
diagnosis of COPD who started treatment with a ICS/LABA com-
bination (index date), were retrospectively followed for 1 year
from the index date to assess the course of oral CS, emergency
department (ED) access, hospital admission, or addition of tio-
tropium (all considered markers of uncontrolled disease). Patients
who received budesonide/formoterol were compared with pa-
tients receiving ﬂuticasone/salmeterol, after adjustment for vari-
ables that might indicate a different propensity to the prescription
(e.g., age, COPD severity as assessed by previous hospitalization or
course of oral CS). Therefore, 1131 patients with COPD who started
treatment with budesonide/formoterol at the index date were
compared with 1131 matched patients with COPD who started
treatment with ﬂuticasone/salmeterol. In the ensuing year, the
odds ratio (OR) for course of oral CS (OR 0.85, 95% conﬁdence
interval (CI): 0.72e1.0), ED access (OR 0.75, CI: 0.58e0e97,
p < 0.05), hospital admission (OR 0.61, CI: 0.47e0.81, p < 0.05) and
addition of tiotropium (OR 0.71, CI: 0.57e0.89) were all in favour
of the budesonide/formoterol combination. Despite the limita-
tions characteristic of observational studies and the risk of not
having completely controlled for “bias by indication”, these data
suggest that in real life the budesonide/formoterol combination
may be more effective that the ﬂuticasone/salmeterol combina-
tion [21].
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by the PATHOS study. This was a population-based, retrospective,
observational study on a large Swedish database, with the aim to
evaluate the health resources of COPD patients treated with
budesonide/formoterol or ﬂuticasone/salmeterol combinations.
Patients were matched according to the propensity score, thus
making two comparable groups of more than 2700 patients each.
The exacerbation rates in the budesonide/formoterol and ﬂutica-
sone/salmeterol groups were 0.80 and 1.09 per patient-years,
respectively (p < 0.0001), and yearly rates for COPD-related hos-
pitalizations were 0.1 and 0.21, respectively (p < 0.0001). All other
healthcare outcome were also signiﬁcantly reduced with budeso-
nide/formoterol vs ﬂuticasone/salmeterol combination [22,23].
Therefore, also this study suggests that long-termwith budesonide/
formoterol combination was associated with fewer healthcare
utilization-deﬁned exacerbations than ﬂuticasone/salmeterol
combination in patients with moderate and severe COPD.
Recently, new ICS/LABA combinations have been studied in
COPD. Fluticasone furoate/vilanterol is a new combination which
may be used once daily. Some studies have demonstrated the ef-
ﬁcacy and safety of this combination in comparison with mono-
components, on both pulmonary function and exacerbation rate
[24e26]. In particular, in the two replicate 1-year studies, a
pooled analysis demonstrated fewer moderate and severe exacer-
bations in all ﬂuticasone/vilanterol groups (0.93e0.81 exac/pt/yr)
in comparisonwith vilanterol alone (1.11 exac/pt/yr) [26]. The other
new combination, beclometasone/formoterol combination in the
extraﬁne formulation, has been demonstrated more effective that
formoterol alone in reducing the rate of moderate and severe ex-
acerbations (OR: 0.72, CI: 0.62e0.84) [27]. Because data on these
newcombinations are limited, theywere not included in the overall
evaluation of efﬁcacy and safety of ICS/LABA combinations in COPD.
4. Potential side effects of ICS in COPD: the risk of pneumonia
Long-term treatment with ICS has been associated with some
potential side effects in patients with COPD. The most frequently
reported systemic side effects, apart from adrenocortical suppres-
sion, are osteoporosis, bone fractures, skin thinning and purpura.
These events have been largely considered in several long-term
studies on the efﬁcacy of ICS alone or in combination with an
LABA [17,28e31]. In general, there is consensus on some negative
effects on bone turnover in subgroups of COPD patients receiving
long-term treatment with high doses of ICS, but the risk of bone
fractures is not higher in the total population of patients with COPD
[29,31]. Skin bruising has been reported frequently in patients with
COPD treated with high-dose ICS, but when this effect was cor-
rected by the use of oral CS cycles, the effect was no longer sig-
niﬁcant [30,31]. Relatively infrequent side effects include glaucoma,
cataracts, diabetes mellitus and weight gain; these side effects may
occasionally be observed in COPD patients, but in general they do
not represent serious adverse events [28]. More recently, great
attention has been focused on the potential to increase the risk of
pulmonary infections like pneumonia. This point is potentially
important considering the well-known immunomodulatory effect
of ICS.
In asthma, a recent meta-analysis of several long-term studies
using inhaled budesonide, alone or in combinationwith formoterol,
has revealed a reduced risk of pneumonia in COPD patients treated
with ICS, while the risk of severe pneumonia (leading to hospital-
ization or death) was slightly but not signiﬁcantly increased in all
patients, particularly in adolescents and adults, and inwomen [32].
The TORCH study revealed an increased risk of pneumonia in
COPD patients treated with ﬂuticasone, alone and in combination
with salmeterol [17]. A detailed subgroup analysis showed anincreased risk of pneumonia ﬂuticasone/salmeterol versus ﬂutica-
sone (19.3% and 18.3%, respectively, p < 0.001), but no increase in
the risk of death from pneumonia, in patients taking ﬂuticasone or
ﬂuticasone/salmeterol. The risk was higher in patients with more
severe COPD, in particular in patients with GOLD stage 4 and in
patients with Medical Research Council (MRC) dyspnoea scores of
4e5 [33,34]. In the INSPIRE study, a similarly increased risk of ex-
acerbations treated with antibiotics was observed in patients
treated with a ﬂuticasone/salmeterol combination compared to
patients treated with tiotropium (7.6% vs 3.6%, respectively,
p < 0.008) [35]; moreover, a one-year study comparingﬂuticasone/
salmeterol combination with ﬂuticasone alone also showed similar
results (4.5% vs 1.4% in FS and F respectively, p < 0.05) [36]. A more
detailed analysis of the TORCH and INSPIRE studies revealed an
excess risk of 3.6 pneumonia events per 100 patients and of 5.7
events per 100 patients, respectively, corresponding to a number
needed to treat (NNT) of 28 and 18 patients, in patients treatedwith
ﬂuticasone.
In contrast, a similar risk of pneumonia has not been reported in
patients with COPD receiving budesonide/formoterol. A meta-
analysis of seven long-term studies with budesonide alone or
with budesonide/formoterol combinations found an hazard ratio
(HR) of 1.05 (CI: 0.81e1.37) for pneumonia-related adverse events
in patients treated with budesonide [37]. The main results from the
major long-term studies with ﬂuticasone/salmeterol and budeso-
nide/formoterol combinations on this point are summarised in
Table 2.
A recent meta-analysis of the risk of pneumonia in patients with
COPD treated with ICS included 17 studies with ﬂuticasone or ﬂu-
ticasone/salmeterol, seven studies with budesonide or budesonide/
formoterol, and one study with mometasone; more than 20,000
patients with COPD were examined. The adjusted OR for pneu-
monia was 1.67 (CI: 1.47e1.89) for ﬂuticasone-treated patients
(p < 0.0001), 1.19 (CI: 0.92e1.53) for budesonide-treated patients
(no signiﬁcant), and 2.00 (CI: 0.83e4.81) for mometasone (not
signiﬁcant) [38]. This observation clearly demonstrates that ﬂuti-
casone, but not budesonide (fewer data are available for other ICS
including mometasone) are responsible for an increased risk of
pneumonia; however this does not appear to translate into
increased overall mortality.
More recently, an interesting population-based cohort study
was conducted on the risk of pneumonia in patients with COPD
treated with ICS [39]. Patients were identiﬁed from the Quebec
database according to consumption of inhaled respiratory drugs
(patients >55 yrs were included to minimize inclusion of asth-
matics patients, in addition to the use of antileukotriene drugs). The
index date was the time of the ﬁrst ICS/LABA combination pre-
scription, after which they were followed until the ﬁrst occurrence
of severe pneumonia (leading to hospitalization or death). Patients
were matched with controls by age and COPD severity, determined
by drug and health resource consumption. ICS dosage was recor-
ded. The adjusted OR for severe pneumonia was higher for ﬂuti-
casone (2.1) than for budesonide (1.17) or other ICS (1.41). There
was also a clear dose response curve with ﬂuticasone (OR
increasing from 1.46 with low dose to 2.21 with high dose) but not
with budesonide (OR 1.05 with low dose and 1.13 with high dose).
This was clear from differences in dose-dependent curves of the
risk of severe pneumonia for patients with COPD receiving ﬂuti-
casone or budesonide (Fig. 1).
Also the previously mentioned PATHOS study supported this
observation [23]. Compared with budesonide/formoterol combi-
nation, rate of pneumonia and admission to hospital were higher in
patients treated with ﬂuticasone/salmeterol combination, with a
rate ratio 1.73 (CI: 1.57e1.90; P < 0.001) and 1.74 (1.56e1.94;
P < 0.001), respectively. The pneumonia event rate per 100 patient
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formoterol combination was 11.0 (10.4e11.8) versus 6.4 (6.0e6.9)
and the rate of admission to hospital was 7.4 (6.9e8.0) versus 4.3
(3.9e4.6). The mean duration of admissions related to pneumonia
was similar for both groups, but mortality related to pneumonia
was higher in the ﬂuticasone/salmeterol group (97 deaths) than in
the budesonide/formoterol group (52 deaths) (hazard ratio 1.76,
1.22 to 2.53; P ¼ 0.003). All cause mortality did not differ between
the treatments (1.08, 0.93 to 1.14; P ¼ 0.59).
In the two replicate 1-year studies comparing ﬂuticasone furo-
ate/vilanterol with vilanterol alone in COPD patients, all groups
treated with ﬂuticasone/vilanterol showed a higher prevalence of
pneumonia (5.9e6.8%) than vilanterol group (3.3%) [26], conﬁrm-
ing the higher risk of ﬂuticasone in favouring non fatal pneumonia.
This is in agreement with the further higher retention time in the
airways of ﬂuticasone furoate in comparison with ﬂuticasone pro-
pionate [40].
The mechanism by which ﬂuticasone increases the risk of
pneumonia at the doses used in clinical trials, while reducing the
total number and severity of exacerbations, is not obvious. A hy-
pothesis has been proposed, based primarily on the observation
that pneumonia often occurs in the weeks following an unresolvedTable 2
Main efﬁcacy results on some endpoints and the risk of pneumonia in COPD patients tre
Treatment (mg/bid) Reduction of
exacerbations rate
Im
Calverley et al.,
2003 TRISTAN study,
1 year duration (13)
SFC 50/250 vs PL 35% (total exacerbations) 0
P
P
SFC 50/250 vs FP 250 7% (total exacerbations) 0
P
P
SFC 50/250 vs SAL 50 4% (total exacerbations) 0
P
P
Calverley et al., 2007
THORC study,
3 years duration (14)
SFC 50/250 vs PL 25% (moderate/severe
exacerbations)
0
P
SFC 50/250 vs FC 250 9% (moderate/severe
exacerbations)
0
P
SFC 50/250 vs SAL 50 12% (moderate/severe
exacerbations)
0
P
FP 250 vs PL 18% (moderate/severe
exacerbations)
0
P
SAL 50 vs PL 15% (moderate/severe
exacerbations)
0
P
Calverley 2003,
1 year duration (15)
BF 320/9 vs PL 23.6% 1
BF 320/9 vs B 320 25.5% 1
BF 320/9 vs F 9 13.6% 5
Szafranski 2003,
1 year duration
BF 320/9 vs PL 24% (1.9e41.4)
P ¼ 0.035e
1
P
BF 320/9 vs B 320 11% (15.9e31.8
P ¼ 0.385)e
9
P
BF 320/9 vs F 9 23% (0.8e40.1
P ¼ 0.043)e
1
P
FEV1 ¼ forced expiratory volume in the ﬁrst second; SGRQ ¼ St. George's Respiratory Q
pionate; BF ¼ budesonide/formoterol; B ¼ budesonide; F ¼ formoterol; PL ¼ placebo.
a Difference in adjusted mean change in post-bronchodilator FEV1 averaged over the
b Difference in adjusted mean change in SGRQ score averaged over the study time, (9
c P < 0.001 for the comparisons between the group receiving salmeterol plus ﬂuticason
d Difference between different group of treatment in the variation of FEV1 from the im
e Increase%, (95% CI), P value.exacerbation [41]. Patients with COPD often have a spectrum of
pathogens colonising the lower airways. Whereas the incidence of
de novo pneumonia not preceded by exacerbation of symptoms is
not greatly increased by ICS use, protracted unresolved infective
exacerbations are associated with a 70% increase in the risk of
pneumonia. This is likely because the airway infections responsible
for the exacerbation, and the consequent airway inﬂammation, are
not adequately controlled by the innate immune system and the ICS
treatment, thus allowing infection/inﬂammation to penetrate to
alveoli and pleural space. While all ICS can suppress local innate
immunity, immunosuppression with ﬂuticasone against pneu-
monia pathogens has been demonstrated [42]. This may be
explained by the high lipophilicity of ﬂuticasone mentioned above,
which results in a high retention time in the mucus and therefore
higher airway concentrations than ICS like budesonide [10]. In an
experimental model, the inhibition of human alveolar macrophage
function occurred at much lower concentrations of ﬂuticasone than
budesonide [43]. In effect, human phagocytic cells initiate type-1
immune responses on exposure to a bacterial (LPS) challenge in
the lower airway spaces, and this immediate response includes an
increase in Th1 cytokines like IL-6 and TNF-alfa. For these two cy-
tokines, ﬂuticasone was 10-fold more potent that budesonide atated with FS or BF combinations, in the major RCTs of 1 year at least duration.
provement in FEV1 Improvement in qol
(evaluated by SGRQ)
Risk of pneumonia
(% of patients with
pneumonia during treatment)
.132 L (0.105e0.161)
< 0.0001
re-bronc FEV1
2.2 (3.3 to 1.0)
P < 0.0005b
No data
.095 L (0.067e0.122)
< 0.0001
re-bronc FEV1
1.4 (2.5 to 0.2)
P < 0.05b
.073 L (0.046e0.101)
< 0.0001
re-bronc FEV1
1.1 (2.2 to 0.1)
P ¼ 0.07b
.092 L (0.075e0.108)
< 0.001a
3.1 (4.1 to 2.1)
P < 0.001b
FSC 50/500: 19.6%c
FP 500: 18.3%c
SAL 50: 13.3%
PL: 12.3%
.044 L (0.028e0.061)
< 0.001a
1.2 (2.1 to 0.2)
P < 0.02b
.050 L (0.034e0.067)
< 0.001a
2.2 (3.1 to 1.2)
P < 0.001b
.047 L (0.031e0.064)
< 0.001a
2.0 (2.9 to 1.0)
P < 0.001b
.042 L (0.025e0.058)
< 0.001a
1.0 (2.0 to 0)
P < 0.06b
4%P < 0.001d Total score of active
treatment
versus placebo
(differences at
12 months):
BF 320/9 vs PL: 7.5
BF 320 vs PL: 3
F 9 vs PL: 4.1
BF 320/9: 3%
B: 400: 2%
F 9: 3%
PL: 1%
1%P < 0.001d
% P ¼ 0.002d
5% (11.0e19.1)
< 0.001e
Mean reductions in
total score at
12 months from
baseline
BF 320/9: 3.9
P ¼ 0.009
BF 320: 1.9
F 9: 3.6
PL: 0.03
No data
% (5.4e13.1)
< 0.001e
% (2.2e4.9)
¼ 0.487e
uestionnaire FSC ¼ ﬂuticasone/salmeterol; SAL ¼ salmeterol; FP ¼ ﬂuticasone pro-
study time, (95% CI), P value.
5% CI), P value.
e propionate and the placebo and between ﬂuticasone group and the placebo group.
provement seen during the run in period.
Fig. 1. Dose-dependent risk of pneumonia in patients with COPD treated with ﬂuti-
casone (blue) or budesonide (red). Dashed lines represent 95% CIs; doses are in mg,
measured in ﬂuticasone equivalents. (reproduced with permission from Suissa et al.,
[32]). (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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macrophages.
5. Final considerations
ICS are important drugs for managing asthma and COPD. They
are recommended for patients with COPD who have severe airﬂow
limitation and/or frequent exacerbations, in combination with
LABA [3]. However, individual ICS differ with respect to several
pharmacologic properties, which may lead to different clinical ef-
fects. Regarding efﬁcacy, ﬂuticasone and budesonide appear to be
equally effective when used alone or in combination with LABA in
patients with COPD, although the majority of studies employed
higher dosages of ﬂuticasone. Budesonide has several favourable
pharmacologic features, and in COPD the budesonide/formoterol
combination is at least as effective as higher doses of ﬂuticasone/
salmeterol combination. On the other hand, budesonide is associ-
ated with a lower risk of pneumonia and severe pneumonia, related
to the different doses administered and the different pharmaco-
logic proﬁles of these two ICS.
Therefore, a comprehensive evaluation of the risk/beneﬁt ratio
should be made when deciding on the type of ICS/LABA combina-
tion to recommend for patients with COPD.
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